Unicycive shares edge up as biotech looks to June FDA meeting and analyst lifts target
Unicycive shares slipped 0.4% to $7.20 in premarket trading Thursday as investors awaited an FDA decision on oxylanthanum carbonate, due June 29. Benchmark raised its price target to $18. The company reported $57.1 million in cash as of May 11 and said it expects funding to last into 2027. No new company update has been issued since May 12.